Skip to main content
Watch Insiders
CADLHealthcare

Candel Therapeutics Inc (CADL) Insider Trading

In the last 90 days, 2 Candel Therapeutics Inc (CADL) insiders reported no open-market purchases and 2 sales totaling $3,244,771. Source: SEC Form 4 filings.

SEC-reported filing activity is provided for research purposes and is not investment advice.

90-day C-suite buyers
0
90-day purchase value
$0.00
Corporate buyers
0
Latest transaction
Sep 11, 2026

Executive filings

Open-market transaction history

Purchase and sale summaries are ordered by the latest reported transaction date.

Open-market insider purchase and sale transactions
DateInsider nameRoleTypeSharesPriceTotal value
Sep 11, 2026Paul Peter TakChief Executive OfficerSale280,245$11.28$3,160,771
Aug 17, 2026Seshu TyagarajanChief Technology OfficerSale7,000$12.00$84,000
Jun 29, 2026Seshu TyagarajanChief Technology OfficerSale7,000$10.02$70,151
Jun 29, 2026Francesca BaroneChief Scientific OfficerSale23,447$10.06$235,769

Common questions

CADL insider trading FAQ

Are CADL insiders buying or selling?
Over the last 90 days, CADL insiders were net sellers, reporting $0.00 of open-market purchases and $3,244,771 of sales.
When was the last CADL insider purchase?
No open-market insider purchase of Candel Therapeutics Inc stock was reported in the last 90 days.
Where does CADL insider trading data come from?
Watch Insiders reads the SEC Form 4 filings that Candel Therapeutics Inc officers, directors, and 10% owners submit to EDGAR, and refreshes this page daily.